The 67th Annual Meeting of the American Society for Radiation Oncology (ASTRO25) takes place in San Francisco from September 27 to October 1, 2025, at the Moscone Center.
This premier gathering unites radiation oncologists, researchers, and industry leaders from around the globe. Tailored for radiation oncologists, medical physicists, radiation therapists, and oncology professionals, ASTRO 2025 presents an extensive program aimed at reimagining radiation medicine, investigating emerging clinical applications, and advancing research and patient care in radiation therapy. Attendees can look forward to state-of-the-art scientific sessions, engaging educational presentations, and exhibits highlighting the latest innovations in radiation oncology.
Nataliya Kovalchuk, Clinical Professor at Stanford Radiation Oncology, shared some key highlights from they 67th Annual Meeting of the American Society for Radiation Oncology (ASTRO25) in San Francisco:
“Immensely grateful to the American Society for Radiation Oncology (ASTRO) for their support for Ukraine.
Heartfelt gratitude for the complimentary ASTRO25 registrations for our Ukrainian colleagues during the war!”
“ASTRO25 presidential symposium by Sameer Keole ‘Radiation Therapy for Benign Conditions‘ delivered insightful highlights on expanding radiotherapy beyond cancer across various conditions:
- heterotopic ossification
- keloids
- plantar fasciitis
- pterygium
- osteoarthritis
- Peyronie’s disease
- Dupuytren’s contracture
- Ledderhose disease
A big thank you to the expert speakers, Drs. Jarad Martin Gopal Bajaj, MD, MBA, FASTRO, Heidi Prather and Paul Werker.
It’s inspiring to see the ways radiation can be used for benign indications.
Looking forward to more illuminating sessions at ASTRO25 American Society for Radiation Oncology.”
“ASTRO25 Presidential symposium:
Coding Relief: ‘Billing RT for Nonmalignant Diseases’ with Dr. Amar Rewari, MD, MBA, FASTRO from Luminis Health in Annapolis.
New coding for radiotherapy in US is upon us.
Here are the changes.”
“ASTRO25: Exciting findings from the NRG-GU005 trial!
This study compared SBRT (36.25 Gy in 5 fx) to moderately hypofractionated IMRT in patients with localized intermediate-risk prostate cancer.
Key Takeaways:
HRQOL Results: SBRT showed significantly fewer patients experiencing declines in bowel health-related quality of life (HRQOL) compared to M-IMRT (34.9% vs. 43.8%, p=0.034)!
Urinary Outcomes: No significant difference in urinary health-related quality of life between the two treatments.
DFS Insights: Unfortunately, no improvement in disease-free survival for SBRT over M-IMRT was observed at the 3-year mark (SBRT: 88.6% vs. IMRT: 92.1%).
Biochemical failure at 3 year: SBRT 8% vs 4%
Per discussant, PACE-B prescriprion of 40Gy might be preferrable.”
Read more posts featuring ASTRO25 on OncoDaily.
